The calls have become all too familiar. People who know that I’m friends with a bunch of top-notch doctors who actually treat COVID call up desperately searching for someone who will help. Last week, I got a call from a family member of a 47-year-old diabetic who suffers from epilepsy and hypertension who was in a Maryland hospital on BiPAP with a blood oxygen level of 83. This man kept away from people for two years and got three shots, but they failed him, and now he was getting nothing but the dangerous remdesivir. Oh, and the monoclonal antibodies are not available. This man now suffers the fate of hundreds of thousands of other people who are victims of therapeutic nihilism.
Just how much does the federal government want to choke off all forms of outpatient treatment for COVID, despite the evidence of so many affective therapeutics? As they make the monoclonal antibody treatments scarcer by the day, the NIH has now manipulated its own website to cover up its original position on ivermectin.
In October, I referred people to the NIH’s chart 2E, which placed ivermectin and nitazoxanide on the same footing as remdesivir in potential antiviral agents against COVID. At the time, I noted that while the NIH admitted in the chart that remdesivir (a big money-maker for hospitals) has the potential to cause kidney failure and liver toxicity, ivermectin and nitazoxanide were given the distinction of “generally well tolerated,” which is a term used to describe a near-perfect drug. I warned people to screenshot it (available on the Wayback Machine), lest the NIH remove or modify the page.
Well, it turns out that after many of us exposed the agency’s own position on ivermectin, it indeed removed the page, and instead, the URL takes you to an updated chart “2F” with changes. Updated on Dec. 16, the new chart specifically says that remdesivir is approved and the other two drugs are not. Additionally, it removes the status of “generally well tolerated” from ivermectin and nitazoxanide.
Here is a screenshot of the old 2E chart of side effects of ivermectin and nitazoxanide:
(bigger)
Now here is the updated version without the “generally well tolerated” status:
(Bigger)
Remember, the original chart was updated on July 8, 2021, well into the pandemic. Nothing has changed since July other than ivermectin becoming mainstream in public knowledge. The approval status was the same then as it is now, and there is zero evidence of more side effects. In fact, millions of doses have been administered without incident, and certainly much more safely than remdesivir. Even if one were to suggest that the NIH is dinging ivermectin based on its own lies and rumors about people getting sick from overdosing on the horse paste (because government has made it hard to get the human pills), how could officials possibly take the distinction away from nitazoxanide? It’s too rare and expensive for people to use, and there is little evidence people used it, much less had adverse reactions to this very safe drug.
Keep in mind that remdesivir is not even a fully approved FDA drug, while the other two have been approved for years with stellar safety profiles. The market category for remdesivir is still listed on the FDA National Drug Code Directory as “Unapproved Drug Other” and shows end marketing dates of 9/20/23 and 8/31/22. Both nitazoxanide and ivermectin, on the other hand, are categorized as FDA-approved drugs.
Indeed, it would be quite illuminating to get hold of FOIA documents of correspondence leading up to these changes.
Fair Use Excerpt. Read the whole article here.
